Skip to content
lifestyle.travelshq.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Pyrotech Therapeutics
Pyrotech Therapeutics Doses First Subject in Phase 1 Study of PTT-121, the World’s First Selective GSDMD Inhibitor to Enter Clinical Development
September 1, 2026